Date: March 31, 2021

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 mRNA Vaccine BNT162b2 (Pfizer-BioNTech)

- ADMINISTRATION has been revised to indicate that:
  - The vaccine should be allowed to come to room temperature prior to dilution.
  - The contents of the vaccine should be allowed to settle for 20 seconds after the final inversion.

Please remove page numbers: 1-5 dated March 2021
Please add new page numbers: 1-5 dated March 31, 2021

AstraZeneca/COVISHIELD COVID-19 Vaccine Aftercare Sheet

- An aftercare sheet has been developed specifically for the AstraZeneca/COVISHIELD COVID-19 vaccines. This aftercare sheet should be provided to recipients of these vaccines. The aftercare sheet includes information regarding rare side effects (blood clots and/or bleeding) of the vaccine that have been reported in Europe. A list of symptoms for which vaccine recipients should seek immediate medical attention has been included.

Please add new page numbers: 1-2 dated March 2021

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated March 2021, and replace with the enclosed updated Title Page and Table of Contents dated March 31, 2021.
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer                     BC Ministry of Health, Population &
Dr. Bonnie Henry                             Public Health Division:

Dr. Reka Gustafson                           Brian Sagar
Vice President, Public Health &              Senior Director Communicable
Wellness, PHSA & Deputy Provincial           Disease, Population and Public Health
Health Officer                               Division

Deputy Provincial Health Officer             Bernard Achampong
Dr. Martin Lavoie                            Executive Director,
                                            Public Health, Planning and Prevention,
                                            Population and Public Health Division